Options Update: Onyx Pharma (ONXX) & Google (GOOG)
Onyx Pharma (ONXX)
ONXX March volatility elevated at 66.
ONXX, a developer of cancer therapies, is recently is expected to report Q4 EPS on February 19.
LEER say's, "We are lowering our US Nexavar sales estimate to $44M from $49M to account for the increased competition in the kidney cancer (RCC) market that management highlighted recently."
ONXX has projected the next key clinical event will be in the 2nd half of 2008 for Phase 3 non-small cell lung cancer.
ONXX is partner of BAY, a German pharmaceutical conglomerate.
ONXX March option implied volatility of 66 is above its 26-week average of 55, suggesting larger price risks.
GOOG February volatility at 58, March at 44 & June at 40 into EPS.
GOOG is recently up $9.94 to $558.26.
GOOG is expected to report Q4 EPS $4.45.
GOOG February option implied volatility of 58 is above its 26-week average of 37, suggesting larger price movement.
View Paul Foster's post archive >